General Gastro News Articles

Gastro

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cui DJ – Although this therapeutic strategy may seem to be cost–efficient and reduce the risk of side effects, recent trials and case reports have shown that top–down therapy using infliximab induces a rapid clinical response, enhances patient quality of life, promotes mucosal healing, reduces surgeries and indirect cost of treatment for patients with severe UC. Moreover, since long–term treatment with infliximab is safe and well tolerated, early aggressive top–down therapeutic strategy may be a more effective approach, at least in a subgroup of severe extensive UC patients.

Related Articles

Medical Management of Ulcerative Colitis
Digestive Diseases, 11/09/09    Relevance Score: 70%

Oxidized Form Of A Common Vitamin May Bring Relief For Ulcerative Colitis
ScienceDaily, 10/02/09    Relevance Score: 69%

Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
Gastroenterology, 10/06/09    Relevance Score: 68%

Leukocyte apheresis in the management of ulcerative colitis
Saudi Journal of Gastroenterology, 10/05/09    Relevance Score: 68%

Ulcerative Colitis Treatment Reduces Need For Surgery By Almost Half, Study Suggests
ScienceDaily, 10/02/09    Relevance Score: 68%

Today in Inflammatory Bowel Dz...keeping you current

An evidence-based review of natalizumab therapy in the management of Crohn’s disease
Therapeutics and Clinical Risk Management, 12/01/09

Appendiceal Mucocele Detected under Treatment of Ulcerative Colitis
Case Reports in Gastroenterology, 11/25/09

Pyoderma Gangrenosum in Crohn's Disease: Unusual Presentation and Management
Case Reports in Gastroenterology, 11/25/09

Today in Pharmacology/kinetics...keeping you current

An evidence-based review of natalizumab therapy in the management of Crohn’s disease
Therapeutics and Clinical Risk Management, 12/01/09

Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer
Cancer Chemotherapy and Pharmacology, 12/01/09

Optimizing the treatment of chronic viral hepatitis C
Expert Review of Gastroenterology & Hepatology, 11/30/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address